S100B in bone marrow aspirates in healthy individuals and malignant melanoma patients.

Abstract:

:The aim of this study was to evaluate S100B in bone marrow (BM) plasma from malignant melanoma patients. BM aspirates and peripheral blood (PB) plasma from 56 patients and BM aspirates from 29 healthy volunteers were collected. S100B was measured using an immune radiometric assay, which is a two-site sandwich assay based on monoclonal antibodies recognizing the beta-subunit. In the control population, the median S100B level in BM plasma was 9.0 microg/l (26 women and three men), an unexpectedly high value compared with the median S100B level in PB<0.05 microg/l. S100B levels in BM seems to be sex dependent. Median S100B levels in samples taken from male melanoma patients was 26.7 microg/l in contrast to 9.3 microg/l in female patients (Mann-Whitney P<0.002). The elevated BM S100B in melanoma patients could not be explained by presence of melanoma cells in the BM, as the values also were increased to the same extent in patients with no detectable BM metastases. In attempts to identify the source of S100B in BM, cytospins from five patients with high S100B values were stained, but none of the BM cells stained positive. S100B levels in PB were dependent on the stage of melanoma disease and there was a significant shorter survival time in the group of patients with elevated S100B compared with the group with normal S100B values, (log rank test: P=0.04). In BM taken from melanoma patients, however, there were no association between S100B levels and survival. The median S100B level in BM aspirates from healthy female volunteers and BM samples from female melanoma patients were 8.1 and 9.3 microg/l both manifold higher than the cut-off value for S100B in PB (0.2 microg/l). The median S100B in the samples taken from male melanoma patients was nearly three times higher than in the female patients. Unlike S100B in PB, S100B in BM demonstrated no prognostic value. The explanation for the unexpected high S100B in BM remains elusive.

journal_name

Melanoma Res

journal_title

Melanoma research

authors

Faye RS,Paus E,Maelandsmo GM,Berner A,Høifødt HK,Fodstad Ø,Aamdal S

doi

10.1097/CMR.0b013e3282f623d9

subject

Has Abstract

pub_date

2008-04-01 00:00:00

pages

134-40

issue

2

eissn

0960-8931

issn

1473-5636

pii

00008390-200804000-00008

journal_volume

18

pub_type

杂志文章
  • Elevated blood β-2 microglobulin is associated with tumor monosomy-3 in patients with primary uveal melanoma.

    abstract::Prognostic blood biomarkers for patients with uveal melanoma have not been identified. Tumor monosomy-3 is strongly associated with the development of metastatic disease. Tumor expression of human leukocyte antigen class I molecules and insulin-like growth factor (IGF)-1 receptor has also been associated with the deve...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e32835b7154

    authors: Triozzi PL,Elson P,Aldrich W,Achberger S,Tubbs R,Biscotti CV,Singh AD

    更新日期:2013-02-01 00:00:00

  • Inhibition of melanoma growth after treatment with dendritic cells in a Tyr-SV40E murine model requires CD4+ T cells but not CD8+ T cells.

    abstract::Melanomas are promising targets for immunotherapy, as they express a number of tissue-specific antigens against which immune responses can be elicited. We have previously described transgenic mice in which malignant cutaneous melanomas are produced. The 1042 melanoma cell line, derived from a primary melanoma in one o...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200412000-00019

    authors: Milling SW,Sai T,Silvers WK,Mintz B

    更新日期:2004-12-01 00:00:00

  • Phase I-II trial of hyperthermic isolated limb perfusion with cisplatin in the treatment of high risk malignant melanoma of the extremities.

    abstract::Between 1983 and 1990, 59 patients with malignant melanoma were retrospectively reviewed to assess the safety, efficacy and the maximal tolerated dose of cisplatin used in hyperthermic isolated limb perfusion. The median follow-up was 29 months (range 3-54 months). The local recurrence rate was 12% in Stage I, 33% in ...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章

    doi:10.1097/00008390-199104000-00007

    authors: Hajarizadeh H,Mueller CR,Woltering EA,Small K,Fletcher WS

    更新日期:1991-04-01 00:00:00

  • Results of cisplatin hyperthermic isolation perfusion for stage IIIA and IIIAB extremity melanoma.

    abstract::Between 1983 and 1992, 21 patients with extremity stage IIIA or IIIAB melanoma underwent hyperthermic isolation limb perfusion (HILP) with cisplatin in dosages varying from 26 to 237 mg/m2 as part of a pharmacokinetics and maximum-tolerated dose study. Extremity temperatures were up to 40 degrees C and the pH was cont...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章

    doi:

    authors: Fletcher WS,Pommier R,Small K

    更新日期:1994-03-01 00:00:00

  • Selective in vivo and in vitro incorporation and accumulation of phenolic thioether amine into malignant melanoma and identification of a (58 kD) binding glycoprotein.

    abstract::Our previous in vivo studies indicated that a phenolic thioether amine (PTEA), 4-S-cysteaminylphenol (CAP), selectively disintegrates melanocytes of black hair and skin, and inhibits the growth of murine and human malignant melanomas. To elucidate the mechanism of the in vivo melanocytotoxicity and anti-melanoma effec...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199211000-00002

    authors: Yamada K,Jimbow K

    更新日期:1992-11-01 00:00:00

  • Comparison of in vivo anti-melanoma effect of enantiomeric alpha-methyl- and alpha-ethyl-4-S-cysteaminylphenol.

    abstract::Melanogenesis appears to be a unique target to develop anti-tumour agents specific for malignant melanoma. Among the anti-melanoma compounds that we have examined, 4-S-cysteaminylphenol (4-S-CAP), a phenolic amine, was found to have the most promising anti-melanoma effects. To further improve the efficacy as anti-mela...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200404000-00006

    authors: Yukitake J,Otake H,Inoue S,Wakamatsu K,Ito S

    更新日期:2004-04-01 00:00:00

  • Redox regulation of Brn-2/N-Oct-3 POU domain DNA binding activity and proteolytic formation of N-Oct-5 during melanoma cell nuclear extraction.

    abstract::Reversible oxidation sensitivity of N-Oct-3 DNA binding activity was seen when melanoma extracts and recombinant Brn-2 protein were treated with a variety of metals, hydrogen peroxide and the cysteine disulphide bond forming agent diamide. Western blot analysis of diamide-oxidized N-Oct-3 protein indicated that this w...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199802000-00002

    authors: Smith AG,Brightwell G,Smit SE,Parsons PG,Sturm RA

    更新日期:1998-02-01 00:00:00

  • Surgical margins in patients with cutaneous melanoma--assessing the adequacy of excision.

    abstract::Appropriate margins of excision for melanoma have been well defined on the basis of prospective clinical trials. Various factors may result in a discrepancy between the intended clinical margin and the pathologic margin ex vivo, however, making it difficult to determine whether adequate excision margins have been obta...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200512000-00009

    authors: Clausen SP,Brady MS

    更新日期:2005-12-01 00:00:00

  • Association between germ cell tumours, large numbers of naevi, atypical naevi and melanoma.

    abstract::Identifying groups of subjects at high risk for the development of melanoma is crucial for the early diagnosis of curable tumours. In the present study, we performed a skin examination in a group of 63 patients followed up after treatment of germ cell tumours (GCTs) who were referred to the dermatologist for multiple ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200104000-00005

    authors: Avril MF,Chompret A,Verne-Fourment L,Terrier-Lacombe MJ,Spatz A,Fizazi K,Bressac-de Paillerets B,Demenais F,Théodore C

    更新日期:2001-04-01 00:00:00

  • Analysis of the expression of intercellular adhesion molecule-1 and MUC18 on benign and malignant melanocytic lesions using monoclonal antibodies directed against distinct epitopes and recognizing denatured, non-glycosylated antigen.

    abstract::Intercellular adhesion molecule (ICAM)-1 and mucin isotype MUC18 were originally identified as melanoma progression antigens by monoclonal antibodies (MAb) generated in a search for molecules expressed by melanomas but not detectable on benign naevi. As MAb detect single epitopes whose accessibility may be modulated, ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:

    authors: Kraus A,Masat L,Johnson JP

    更新日期:1997-08-01 00:00:00

  • Sentinel lymph node dissection in stage I/II melanoma patients: surgical management and clinical follow-up study.

    abstract::Selective sentinel lymph node (SLN) dissection is widely used in the management of cutaneous melanoma patients without clinical evidence of nodal metastases. A series of 274 consecutive melanoma patients who underwent melanoma primary excision and SLN mapping at our institutions since 1998, and were thereafter followe...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章

    doi:10.1097/00008390-200404000-00016

    authors: Macripò G,Quaglino P,Caliendo V,Ronco AM,Soltani S,Giacone E,Pau S,Fierro MT,Bernengo MG

    更新日期:2004-04-01 00:00:00

  • Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa.

    abstract::One of the principal applications of tumour markers is the early detection of recurrent disease in the follow-up of patients. In the study described here, we compared the usefulness of two serum markers for melanoma, 5-S-cysteinyldopa (5-S-CD) and melanoma inhibitory activity (MIA), in the monitoring of postsurgical m...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200208000-00003

    authors: Matsushita Y,Hatta N,Wakamatsu K,Takehara K,Ito S,Takata M

    更新日期:2002-08-01 00:00:00

  • Serum melatonin levels in melanoma patients after repeated oral administration.

    abstract::The goal of this study was to determine the effect of oral melatonin in divided doses on plasma melatonin levels in patients with metastatic melanoma. Hourly blood samples were obtained from five patients for 24 h prior to melatonin administration and for 24 h during oral administration of melatonin, 50 mg every 4 h. ...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章

    doi:10.1097/00008390-199402000-00009

    authors: Kane MA,Johnson A,Nash AE,Boose D,Mathai G,Balmer C,Yohn JJ,Robinson WA

    更新日期:1994-02-01 00:00:00

  • The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.

    abstract::Cerebral metastases from melanoma are correlated with a poor prognosis. Temozolomide is an oral alkylating agent that can cross the blood-brain barrier and in phase II and III trials, patients with advanced metastatic melanoma achieved overall response rates of 13 to 21%. The present study evaluated the efficacy and t...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.cmr.0000136707.60108.ab

    authors: Bafaloukos D,Tsoutsos D,Fountzilas G,Linardou H,Christodoulou C,Kalofonos HP,Briassoulis E,Panagiotou P,Hatzichristou H,Gogas H

    更新日期:2004-08-01 00:00:00

  • Intracellular signaling modules linking DNA damage to secretome changes in senescent melanoma cells.

    abstract::Cellular senescence is a major barricade on the path of cancer development, yet proteins secreted from senescent cells exert complex and often discordant effects on subsequent cancer evolution. Somatic genome alternations driving the formation of nevi and melanoma are efficient inducers of cellular senescence. Melanoc...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000671

    authors: Chavanet A,Hill KR,Jiménez-Andrade Y,Choo MK,White K,Park JM

    更新日期:2020-08-01 00:00:00

  • CDKN2A novel mutation in a patient from a melanoma-prone family.

    abstract::CDKN2A is thought to be the main candidate gene for melanoma susceptibility. Deletion or mutations in the CDKN2A gene may produce an imbalance between functional p16 and cyclin D, causing abnormal cell growth. We here describe a novel mutation consisting of a 1 bp deletion at nucleotide position 201 (codon 67) (CACGGc...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200110000-00002

    authors: Grammatico P,Binni F,Eibenschutz L,De Bernardo C,Grammatico B,Rinaldi R,De Simone P,Catricalà C

    更新日期:2001-10-01 00:00:00

  • Effective treatment of B16 melanoma by direct delivery of bleomycin using electrochemotherapy.

    abstract::Electrochemotherapy (ECT), chemotherapy administered in combination with electric fields, has the potential to be an effective localized treatment for cutaneous malignancies. Bleomycin's cytotoxicity was enhanced by exposing tumour cells to electrical fields following intravenous injection of the chemotherapeutic agen...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199702000-00003

    authors: Heller R,Jaroszeski M,Perrott R,Messina J,Gilbert R

    更新日期:1997-02-01 00:00:00

  • Mutation analysis of the MEN1 tumour suppressor gene in malignant melanoma.

    abstract::During the initiation and progression of malignant melanoma a series of genetic events accumulate, including alterations of chromosome 11q. Recently, an important tumour suppressor gene, the multiple endocrine neoplasia type 1 (MEN1) gene, has been mapped on 11q13 and has been cloned. To assess whether the MEN1 region...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199906000-00006

    authors: Böni R,Vortmeyer AO,Huang S,Burg G,Hofbauer G,Zhuang Z

    更新日期:1999-06-01 00:00:00

  • The progression associated antigen MUC18: a unique member of the immunoglobulin supergene family.

    abstract::The cell surface glycoprotein MUC18 was originally identified as a progression associated antigen in melanoma. MUC18 is expressed most strongly on metastatic lesions and advanced primary tumours and is only rarely detected in benign lesions. cDNA cloning revealed MUC18 to be a novel member of the immunoglobulin superf...

    journal_title:Melanoma research

    pub_type: 杂志文章,评审

    doi:10.1097/00008390-199310000-00006

    authors: Johnson JP,Rothbächer U,Sers C

    更新日期:1993-10-01 00:00:00

  • Use of integrative epigenetic and cytogenetic analyses to identify novel tumor-suppressor genes in malignant melanoma.

    abstract::The objective of this study was to identify novel tumor-suppressor genes in melanoma, using an integrative genomic approach. Data from: (i) earlier reports of DNA loss and gain in malignant melanoma accompanied by comparative genomic hybridization high-definition array data of the entire human genome; (ii) microarray ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e328344a003

    authors: Mithani SK,Smith IM,Califano JA

    更新日期:2011-08-01 00:00:00

  • Skin cancer in children and young adults: 28 years' experience from the Northern Region Young Person's Malignant Disease Registry, UK.

    abstract::Little population-based data has been published about skin cancers in children and young adults. In this study, 200 cases of melanoma and non-melanoma skin cancers diagnosed under 25 years of age in the North of England from 1968-1995 were obtained from the Northern Region Young Persons' Malignant Disease Registry. Th...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/01.cmr.0000056259.56735.eb

    authors: Pearce MS,Parker L,Cotterill SJ,Gordon PM,Craft AW

    更新日期:2003-08-01 00:00:00

  • Linkage analysis in Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome families. Effect of naevus count.

    abstract::Familial atypical multiple mole-melanoma (FAMMM) syndrome is characterized by the familial occurrence of malignant melanoma of the skin in combination with multiple atypical precursor naevi. In the present study we performed linkage analysis in seven Dutch FAMMM families to define the relationship between the ultimate...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:

    authors: Gruis NA,Sandkuijl LA,Weber JL,van der Zee A,Borgstein AM,Bergman W,Frants RR

    更新日期:1993-08-01 00:00:00

  • Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases.

    abstract::Proteomics provides a powerful approach for screening alterations in protein expression and post-translational modification associated with particular human diseases. In this study, the analysis of protein expression was focused on malignant melanoma in order to determine the candidate genes involved in tumour progres...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200508000-00002

    authors: Carta F,Demuro PP,Zanini C,Santona A,Castiglia D,D'Atri S,Ascierto PA,Napolitano M,Cossu A,Tadolini B,Turrini F,Manca A,Sini MC,Palmieri G,Rozzo AC,Italian Melanoma Intergroup.

    更新日期:2005-08-01 00:00:00

  • Defining fast-growing melanomas: reappraisal of epidemiological, clinical, and histological features.

    abstract::The growth rate (GR) of melanomas is not uniform. A fast-growing subtype has been identified and seems to have a role in the stabilization of the mortality rates because of melanoma. To examine features associated with fast-growing melanomas (FGMs) and to determine the relationship between the GR and well-recognized p...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e328342f312

    authors: Martorell-Calatayud A,Nagore E,Botella-Estrada R,Scherer D,Requena C,Serra-Guillén C,Llombart B,Sanmartin O,Kumar R,Guillén C

    更新日期:2011-04-01 00:00:00

  • Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients.

    abstract::Immunotherapy with anti-programmed cell death-1 (PD-1) agents is an effective treatment for metastatic melanoma. Octogenarians and nonagenarians represent a significant cohort of melanoma patients. This multicenter retrospective analysis enrolled 499 patients treated with nivolumab or pembrolizumab. Seventy-three pati...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000705

    authors: Cybulska-Stopa B,Ziętek M,Kamińska-Winciorek G,Czarnecka AM,Piejko K,Galus Ł,Ziółkowska B,Kieszko S,Kempa-Kamińska N,Calik J,Zemełka T,Kubiatowski T,Suwiński R,Mackiewicz J,Rutkowski P

    更新日期:2021-02-01 00:00:00

  • Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

    abstract::BRAF mutations are found in ~50% of metastatic melanomas, most commonly in codon V600. Vemurafenib improves progression-free survival and overall survival in patients with advanced BRAF-mutated melanoma. The results of a descriptive study evaluating vemurafenib in patients with advanced melanoma harbouring BRAF mutati...

    journal_title:Melanoma research

    pub_type: 杂志文章,多中心研究

    doi:10.1097/CMR.0000000000000398

    authors: Hallmeyer S,Gonzalez R,Lawson DH,Cranmer LD,Linette GP,Puzanov I,Taback B,Cowey CL,Ribas A,Daniels GA,Moore T,Gibney GT,Tawbi H,Whitman E,Lee G,Mun Y,Liu S,Hamid O

    更新日期:2017-12-01 00:00:00

  • The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.

    abstract::We have observed that an early increase in the CD4+/CD8+ ratio of metastatic melanoma patients during chemoimmunotherapy is the most favourable independent prognostic factor. In this study, 87 patients with metastatic melanoma were monitored for peripheral blood lymphocyte subsets (CD4+ and CD8+) before and during che...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200412000-00009

    authors: Hernberg MM,Hahka-Kemppinen MH,Pyrhönen SO

    更新日期:2004-12-01 00:00:00

  • Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in human cutaneous melanoma.

    abstract::Cutaneous malignant melanoma is one of the most common and aggressive forms of human cancers and has a poor prognosis. Activation of signal transducer and activator of transcription 3 (STAT3) has been found in several human cancers and is thought to correlate aggressive disease and poor response. In this study, we inv...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e32834acc37

    authors: Wu ZS,Cheng XW,Wang XN,Song NJ

    更新日期:2011-12-01 00:00:00

  • Molecular alterations associated with acquired resistance to BRAFV600E targeted therapy in melanoma cells.

    abstract::Selective inhibition of the mutant BRAF protein is a highly promising therapeutic approach for melanoma patients carrying the BRAF mutation. Despite the remarkable clinical response, most patients develop resistance and experience tumour regrowth. To clarify the molecular background of BRAF inhibitor resistance, we ge...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000588

    authors: Szász I,Koroknai V,Kiss T,Vízkeleti L,Ádány R,Balázs M

    更新日期:2019-08-01 00:00:00

  • The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival.

    abstract::The management of melanoma brain metastases (MBM) includes different therapeutic modalities, such as surgery, radiotherapy and chemotherapy. Despite the choice of treatments, survival remains poor, exceeding 1 year only in patients with solitary metastases and absence of extracranial disease. A total of 115 consecutiv...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000029

    authors: Vecchio S,Spagnolo F,Merlo DF,Signori A,Acquati M,Pronzato P,Queirolo P

    更新日期:2014-02-01 00:00:00